{"id":"https://openalex.org/W2898520904","doi":"https://doi.org/10.1093/annonc/mdy272.296","title":"Exposure-safety analyses in breast cancer patients with germline BRCA1/2 mutations receiving talazoparib (TALA) in EMBRACA and ABRAZO trials","display_name":"Exposure-safety analyses in breast cancer patients with germline BRCA1/2 mutations receiving talazoparib (TALA) in EMBRACA and ABRAZO trials","publication_year":2018,"publication_date":"2018-10-01","ids":{"openalex":"https://openalex.org/W2898520904","doi":"https://doi.org/10.1093/annonc/mdy272.296","mag":"2898520904"},"language":"en","primary_location":{"id":"doi:10.1093/annonc/mdy272.296","doi":"https://doi.org/10.1093/annonc/mdy272.296","is_oa":true,"landing_page_url":"https://doi.org/10.1093/annonc/mdy272.296","pdf_url":null,"source":{"id":"https://openalex.org/S41454044","display_name":"Annals of Oncology","issn_l":"0923-7534","issn":["0923-7534","1569-8041"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of Oncology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://doi.org/10.1093/annonc/mdy272.296","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5087989455","display_name":"Mohamed A. Elmeliegy","orcid":"https://orcid.org/0000-0002-9825-5890","observed_orcids":["https://orcid.org/0000-0002-9825-5890"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M. Elmeliegy","raw_affiliation_strings":["Oncology, Pfizer, Inc., La Jolla, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology, Pfizer, Inc., La Jolla, CA, USA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101745077","display_name":"Yanke Yu","orcid":"https://orcid.org/0000-0002-3276-0130","observed_orcids":["https://orcid.org/0000-0002-3276-0130"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Y. Yu","raw_affiliation_strings":["Oncology, Pfizer, Inc., La Jolla, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology, Pfizer, Inc., La Jolla, CA, USA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014713051","display_name":"Jennifer Keating Litton","orcid":"https://orcid.org/0000-0001-8390-4985","observed_orcids":["https://orcid.org/0000-0001-8390-4985"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J.K. Litton","raw_affiliation_strings":["Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060044961","display_name":"Nicholas C. Turner","orcid":"https://orcid.org/0000-0001-8937-0873","observed_orcids":["https://orcid.org/0000-0001-8937-0873"]},"institutions":[{"id":"https://openalex.org/I4210121186","display_name":"Royal Marsden Hospital","ror":"https://ror.org/034vb5t35","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038","https://openalex.org/I4210121186"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"N.C. Turner","raw_affiliation_strings":["Toby Robins Breast Cancer Research Centre, The Royal Marsden, London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Toby Robins Breast Cancer Research Centre, The Royal Marsden, London, UK","institution_ids":["https://openalex.org/I4210121186"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050035884","display_name":"Akos Gabor Czibere","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"A. Czibere","raw_affiliation_strings":["Oncology, Pfizer, Inc., Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology, Pfizer, Inc., Cambridge, MA, USA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026329970","display_name":"Gary G. Wilson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"G.G. Wilson","raw_affiliation_strings":["Oncology, Pfizer, Inc., New York, NY, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology, Pfizer, Inc., New York, NY, USA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048191133","display_name":"Iulia Cristina Tudor","orcid":"https://orcid.org/0000-0002-4229-2940","observed_orcids":["https://orcid.org/0000-0002-4229-2940"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"I.C. Tudor","raw_affiliation_strings":["Biostatistics, Pfizer, Inc., San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biostatistics, Pfizer, Inc., San Francisco, CA, USA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082477151","display_name":"Jianfeng Zheng","orcid":"https://orcid.org/0000-0003-3178-6432","observed_orcids":["https://orcid.org/0000-0003-3178-6432"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. Zheng","raw_affiliation_strings":["Oncology, Pfizer, Inc., Collegeville, PN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology, Pfizer, Inc., Collegeville, PN, USA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5015033901","display_name":"D.D. Wang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"D.D. Wang","raw_affiliation_strings":["Oncology, Pfizer, Inc., La Jolla, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology, Pfizer, Inc., La Jolla, CA, USA","institution_ids":["https://openalex.org/I180857899"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5080,"currency":"USD","value_usd":5080},"apc_paid":{"value":5080,"currency":"USD","value_usd":5080},"fwci":0.3781,"has_fulltext":false,"cited_by_count":4,"citation_normalized_percentile":{"value":0.64737898,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":97},"biblio":{"volume":"29","issue":null,"first_page":"viii97","last_page":"viii97"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.9911999702453613,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.9911999702453613,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10769","display_name":"BRCA gene mutations in cancer","score":0.007799999788403511,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/talazoparib","display_name":"talazoparib","score":0.9990000128746033},{"id":"https://openalex.org/keywords/parp-inhibitors","display_name":"PARP inhibitors","score":0.7990000247955322},{"id":"https://openalex.org/keywords/germline-brca1-2-mutation","display_name":"germline BRCA1/2 mutation","score":0.8820000290870667},{"id":"https://openalex.org/keywords/advanced-breast-cancer","display_name":"advanced breast cancer","score":0.9390000104904175},{"id":"https://openalex.org/keywords/drug-exposure","display_name":"drug exposure","score":0.5640000104904175},{"id":"https://openalex.org/keywords/dose-adjustment","display_name":"dose adjustment","score":0.5680000185966492},{"id":"https://openalex.org/keywords/anemia","display_name":"anemia","score":0.8899999856948853},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.8529999852180481},{"id":"https://openalex.org/keywords/thrombocytopenia","display_name":"thrombocytopenia","score":0.9990000128746033},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.7770000100135803},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.7429999709129333},{"id":"https://openalex.org/keywords/baseline-hemoglobin","display_name":"baseline hemoglobin","score":0.7829999923706055}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.912644624710083},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6227465867996216},{"id":"https://openalex.org/C2778248108","wikidata":"https://www.wikidata.org/wiki/Q5445","display_name":"Anemia","level":2,"score":0.5990057587623596},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.5838659405708313},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.5822136402130127},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.5419254302978516},{"id":"https://openalex.org/C50382708","wikidata":"https://www.wikidata.org/wiki/Q223218","display_name":"Proportional hazards model","level":2,"score":0.5327717661857605},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.49781131744384766},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.4955493211746216},{"id":"https://openalex.org/C144301174","wikidata":"https://www.wikidata.org/wiki/Q7893852","display_name":"Univariate analysis","level":3,"score":0.42323243618011475},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.38028910756111145},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2985662817955017},{"id":"https://openalex.org/C38180746","wikidata":"https://www.wikidata.org/wiki/Q1952580","display_name":"Multivariate analysis","level":2,"score":0.2070663869380951},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.1510128378868103},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.09353786706924438},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1093/annonc/mdy272.296","doi":"https://doi.org/10.1093/annonc/mdy272.296","is_oa":true,"landing_page_url":"https://doi.org/10.1093/annonc/mdy272.296","pdf_url":null,"source":{"id":"https://openalex.org/S41454044","display_name":"Annals of Oncology","issn_l":"0923-7534","issn":["0923-7534","1569-8041"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of Oncology","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1093/annonc/mdy272.296","doi":"https://doi.org/10.1093/annonc/mdy272.296","is_oa":true,"landing_page_url":"https://doi.org/10.1093/annonc/mdy272.296","pdf_url":null,"source":{"id":"https://openalex.org/S41454044","display_name":"Annals of Oncology","issn_l":"0923-7534","issn":["0923-7534","1569-8041"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of Oncology","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3030907279","https://openalex.org/W4412100411","https://openalex.org/W2792460055","https://openalex.org/W2990079331","https://openalex.org/W3013762877","https://openalex.org/W3204724932","https://openalex.org/W4387809997","https://openalex.org/W3030475138","https://openalex.org/W2806916096","https://openalex.org/W2944637757"],"abstract_inverted_index":{"Background:":[0],"TALA":[1,13,53,127,298],"is":[2],"a":[3,89,174,193],"potent":[4],"PARP":[5],"inhibitor.":[6],"Efficacy":[7],"and":[8,29,55,62,74,125,146,181,198,244,282,292,312,322,338,368,374,383,387],"safety":[9,111,149,263],"profiles":[10],"of":[11,36,109,196,260,273,290,306,341],"once-daily":[12],"1":[14],"mg":[15],"were":[16,86,164,330],"established":[17],"in":[18,24,88,161,167,177],"advanced":[19],"breast":[20],"cancer":[21],"patients":[22],"(pts)":[23],"the":[25,50,64,107,147,207,223,249,303,351],"phase":[26,30],"3":[27,57],"EMBRACA":[28],"2":[31],"ABRAZO":[32],"trials.":[33],"Approximately":[34],"60%":[35],"pts":[37,81,178,185],"experience":[38],"dose":[39,70,95,123],"modification":[40],"due":[41],"to":[42,69,106],"an":[43],"adverse":[44],"event":[45,112,118],"(AE).":[46],"This":[47,300],"analysis":[48],"characterized":[49],"relationship":[51,136,250],"between":[52,137,241],"exposure":[54],"grade":[56],"or":[58],"higher":[59,175,194,203,242,288,297],"anemia,":[60,206],"neutropenia,":[61],"thrombocytopenia,":[63,222],"most":[65],"common":[66],"AEs":[67,308],"leading":[68],"modification.":[71],"Methods:":[72],"Safety":[73],"pharmacokinetic":[75],"(PK)":[76],"data":[77],"from":[78,102,131],"367":[79],"TALA-treated":[80],"(285":[82],"EMBRACA,":[83],"82":[84],"ABRAZO)":[85],"included":[87],"pooled":[90],"analysis.":[91,134],"To":[92],"account":[93],"for":[94,211,227,239,350],"modifications":[96],"over":[97],"time,":[98],"individual":[99],"time-varying":[100],"concentration":[101],"time":[103,108,119],"0":[104],"up":[105],"each":[110,117],"(Cavg,t)":[113],"was":[114,151,200,214,230,246,251,265,275,294],"calculated":[115],"at":[116],"using":[120,153],"average":[121],"daily":[122],"intensity":[124],"apparent":[126],"clearance":[128],"as":[129,139,141],"obtained":[130],"population":[132],"PK":[133],"The":[135],"Cavg,t,":[138],"well":[140],"other":[142],"potential":[143],"prognostic":[144],"factors":[145],"selected":[148],"events":[150,183],"evaluated":[152],"Cox":[154,188],"proportional":[155],"hazard":[156],"(PH)":[157],"models.":[158],"Significant":[159],"covariates":[160],"univariate":[162],"analyses":[163],"further":[165],"examined":[166],"multi-variate":[168],"analyses.":[169],"Results:":[170],"Visual":[171],"examination":[172],"suggested":[173],"Cavg,t":[176,212,228,243],"with":[179,202,267,277,296],"anemia":[180,197,291],"thrombocytopenia":[182,199,293],"vs":[184],"without":[186],"events.":[187],"PH":[189],"models":[190],"indicated":[191],"that":[192],"risk":[195,259,272,289],"associated":[201,266,276,295],"Cavg,t.":[204],"For":[205,221],"HR":[208,224],"(95%":[209,225],"CI)":[210,226],"(ng/mL)":[213,229],"1.3":[215],"(1.12,":[216],"1.4),":[217],"P":[218,234],"=":[219,235,256],"3.03.":[220],"1.2":[231],"(1.01,":[232],"1.3),":[233],"0.0394.":[236],"A":[237,287],"trend":[238],"association":[240],"neutropenia":[245,274],"observed":[247],"although":[248],"not":[252],"statistically":[253],"significant":[254],"(P":[255],"0.0633).":[257],"Higher":[258,271],"all":[261],"tested":[262],"endpoints":[264],"lower":[268,278,283],"baseline":[269],"hemoglobin.":[270],"absolute":[279],"neutrophil":[280],"count":[281],"body":[284],"weight.":[285],"Conclusions:":[286],"exposure.":[299],"finding":[301],"supports":[302],"proposed":[304],"management":[305],"TALA-related":[307],"through":[309],"dosing":[310],"interruption":[311],"reduction.":[313],"Clinical":[314],"trial":[315],"identification:":[316],"NCT01945775,":[317],"NCT02034916.":[318],"Editorial":[319,321],"acknowledgement:":[320],"medical":[323],"writing":[324],"support":[325],"funded":[326],"by":[327,332],"Pfizer":[328,386],"Inc.":[329,354,357,405],"provided":[331],"Edwin":[333],"Thrower,":[334],"PhD,":[335],"Mary":[336],"Kacillas":[337],"Paula":[339],"Stuckart":[340],"Ashfield":[342],"Healthcare":[343],"Communications,":[344],"Middletown,":[345],"Connecticut.":[346],"Legal":[347],"entity":[348],"responsible":[349],"study:":[352],"Pfizer,":[353,356,363,375,404],"Funding:":[355],"Disclosure:":[358],"J.K.":[359],"Litton:":[360],"Institutional-contracted":[361],"research:":[362],"Novartis,":[364],"EMD-Serono,":[365],"AstraZeneca,":[366],"GlaxoSmithKline,":[367],"Genentech;":[369],"Advisory":[370,380],"board":[371],"participation:":[372],"AstraZeneca":[373],"both":[376],"uncompensated.":[377],"N.C.":[378],"Turner:":[379],"board,":[381],"honoraria":[382],"research":[384],"funding:":[385],"BioMarin.":[388],"M.":[389],"Elmeliegy,":[390],"A.":[391],"Czibere,":[392],"Y.":[393],"Yu,":[394],"G.G.":[395],"Wilson,":[396],"I.C.":[397],"Tudor,":[398],"J.":[399],"Zheng,":[400],"D.D.":[401],"Wang:":[402],"Employment:":[403]},"counts_by_year":[{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":1}],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2018-11-02T00:00:00"}